What it's for (Indications)
- Cilostazol is indicated for the reduction of symptoms of intermittent claudication, as demonstrated by an increase in maximum walking distance and pain-free walking distance, in patients with peripheral artery disease (PAD).
- Its therapeutic efficacy is primarily observed in improving the quality of life for individuals whose daily activities are limited by claudication pain, enabling them to walk further before experiencing ischemic discomfort.
- The drug works by improving blood flow to the lower extremities, thereby alleviating the muscle pain or cramping that typically occurs during exercise.
- It is not intended as an acute treatment for critical limb ischemia, nor does it replace comprehensive management strategies for PAD, including risk factor modification.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The recommended dosage of cilostazol is 100 mg orally twice daily, taken at least 30 minutes before or 2 hours after breakfast and dinner. This specific timing relative to meals is crucial to ensure optimal absorption and minimize potential food-drug interactions that could affect bioavailability. Patients should be advised that the therapeutic effects may not be apparent for 2 to 4 weeks, and in some cases, up to 12 weeks of consistent treatment may be required to observe significant improvements in walking distances. If co-administered with strong inhibitors of CYP3A4 (e.g., ketoconazole, itraconazole, erythromycin, diltiazem) or CYP2C19 (e.g., omeprazole), the dose of cilostazol should be reduced to 50 mg twice daily to mitigate the risk of increased systemic exposure and potential adverse effects. Adherence to the prescribed dosing regimen and dietary recommendations is critical for achieving therapeutic efficacy and ensuring patient safety. |
Safety & Warnings
Common Side Effects
- Common adverse reactions associated with cilostazol include headache, diarrhea, abnormal stools, palpitations, and peripheral edema.
- These reactions are generally mild to moderate in severity and often diminish with continued therapy as the patient acclimatizes to the medication.
- More serious, albeit less frequent, adverse events can include tachycardia, angina pectoris, ventricular arrhythmias, and exacerbation of congestive heart failure, particularly in susceptible individuals.
- Due to its antiplatelet effects, there is an increased risk of bleeding, which necessitates careful monitoring in patients with a predisposition to hemorrhage or those on concomitant anticoagulant or other antiplatelet therapies.
- Gastrointestinal disturbances such as nausea, dyspepsia, and abdominal pain are also reported.
- Patients should be counselled to promptly report any unusual bleeding, bruising, or worsening cardiac symptoms (e.
- g.
- , shortness of breath, swelling, rapid heart rate) to their healthcare provider.
Serious Warnings
- Black Box Warning: **WARNING: INCREASED MORTALITY IN PATIENTS WITH CONGESTIVE HEART FAILURE** Cilostazol and its active metabolites are phosphodiesterase 3 (PDE3) inhibitors. Several drugs with this pharmacological effect, specifically other PDE3 inhibitors used in heart failure patients (e.g., milrinone, enoximone), have caused decreased survival in patients with class III-IV congestive heart failure. Accordingly, cilostazol is contraindicated in patients with congestive heart failure of any severity, including asymptomatic left ventricular dysfunction. This contraindication reflects a serious class effect, and although cilostazol has not been specifically studied in patients with advanced heart failure, the potential for harm necessitates this stringent warning. Healthcare providers must thoroughly assess a patient's cardiac history and current status to definitively rule out any degree of heart failure prior to initiating and throughout the entire course of treatment with cilostazol. Any new or worsening symptoms suggestive of heart failure, such as dyspnea, peripheral edema, or rapid weight gain, necessitate immediate discontinuation of cilostazol therapy and comprehensive cardiac evaluation.
- Cilostazol should be used with extreme caution in patients with severe underlying cardiac disease, beyond the absolute contraindication for heart failure, due to its potential to increase heart rate and exacerbate existing arrhythmias or ischemic symptoms.
- Patients with a history of bleeding disorders, recent surgery, or those concomitantly receiving other antiplatelet agents (e.
- g.
- , aspirin, clopidogrel) or anticoagulants (e.
- g.
- , warfarin) should be closely monitored for signs of hemorrhage (e.
- g.
- , epistaxis, gastrointestinal bleeding, hematuria).
- While specific dose adjustments for severe hepatic or renal impairment are not precisely defined in all guidelines, caution is advised, and dose reduction or increased monitoring may be considered due to potential altered metabolism and excretion.
- Pregnancy Category C: cilostazol should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus, given limited human data.
- The excretion of cilostazol into human milk is unknown; therefore, caution is advised in breastfeeding mothers, and a decision to discontinue nursing or the drug should be made considering the importance of the drug to the mother.
How it Works (Mechanism of Action)
Cilostazol exerts its therapeutic effects primarily through the selective inhibition of phosphodiesterase-3 (PDE3) in vascular smooth muscle cells and platelets. This inhibition leads to a significant increase in the intracellular concentration of cyclic adenosine monophosphate (cAMP) by preventing its hydrolysis. In vascular smooth muscle cells, elevated cAMP levels trigger a cascade of intracellular events that result in vasodilation, particularly in the arterial beds of the lower extremities, thereby increasing blood flow and oxygen delivery to ischemic tissues. Concurrently, in platelets, increased cAMP levels powerfully inhibit platelet aggregation and adhesion, reducing the likelihood of thrombus formation and microvascular occlusion. These dual actions of vasodilation and antiplatelet activity are crucial for improving the symptoms of intermittent claudication by enhancing peripheral circulation and preventing ischemic events in the microvasculature. It also exhibits some direct effects on endothelial cells, potentially improving endothelial function.
Commercial Brands (Alternatives)
No other brands found for this formula.